<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF23AA6F-A273-459B-8CD5-EE4DA9D7C86F"><gtr:id>FF23AA6F-A273-459B-8CD5-EE4DA9D7C86F</gtr:id><gtr:name>Intercept Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF23AA6F-A273-459B-8CD5-EE4DA9D7C86F"><gtr:id>FF23AA6F-A273-459B-8CD5-EE4DA9D7C86F</gtr:id><gtr:name>Intercept Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6412E7E3-7E26-493B-81A7-B738B8FD72B4"><gtr:id>6412E7E3-7E26-493B-81A7-B738B8FD72B4</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Fallowfield</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6205"><gtr:id>9137967B-6D32-46B4-9E17-9C7733C321D6</gtr:id><gtr:title>The role of Matrix Metalloproteinase-13 (MMP-13) in the reversibility of liver fibrosis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6205</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>134898</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intercept Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Intercept Pharmaceuticals collaboration</gtr:description><gtr:id>E9AD2668-6DDF-48C4-AD0D-518F9CF41857</gtr:id><gtr:impact>Too early to report.</gtr:impact><gtr:outcomeId>58c13ba01ef332.40432163-1</gtr:outcomeId><gtr:partnerContribution>Proprietary IP. Methodology input. Materials transfer.</gtr:partnerContribution><gtr:piContribution>Study design, execution of the study, data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Regenerative Medicine</gtr:department><gtr:description>Macrophage Therapy for Liver Cirrhosis</gtr:description><gtr:id>EF039D6C-D380-4BEF-B62D-D20CD1BCDD57</gtr:id><gtr:impact>Phase 1 (dose escalation) has commenced.</gtr:impact><gtr:outcomeId>566ee8b9184c41.71056622-1</gtr:outcomeId><gtr:partnerContribution>Clinical imaging, study endpoints, study design.</gtr:partnerContribution><gtr:piContribution>Co-investigator on this MRC funded phase 1/2 clinical trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Discovery Partnerships with Academia</gtr:department><gtr:description>GSK Discovery Partnerships with Academia (DPAc)</gtr:description><gtr:id>D750C302-C643-4CC1-A606-139510CFC5E0</gtr:id><gtr:impact>It is too early for tangible outputs. Manuscript in preparation.</gtr:impact><gtr:outcomeId>CL3bJ1cWxXy-1</gtr:outcomeId><gtr:partnerContribution>Drug discovery. Assay development. Medicinal chemistry. Funding.</gtr:partnerContribution><gtr:piContribution>Background data. Disease models. Clinical need/applications.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Life Sciences</gtr:department><gtr:description>Liver fibrosis - image analysis and tissue biomarkers</gtr:description><gtr:id>AC61FC59-23BF-4D1B-8EFF-10880C55A36C</gtr:id><gtr:impact>Abstracts at BASL and AASLD conferences 2013.
Joint Edinburgh/Nottingham manuscript in preparation.
Application for funding from Nottingham Molecular Pathology Node.</gtr:impact><gtr:outcomeId>gZvxKZJQaZQ-1</gtr:outcomeId><gtr:partnerContribution>Clinical disease cohort. Histology and image analysis platforms.</gtr:partnerContribution><gtr:piContribution>Liver fibrosis and elastin - biological understanding, human tissue samples, immunohistochemistry, automated analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC mouse network</gtr:description><gtr:id>1BA15448-A9C9-4EC9-9E1B-3D464D089AD1</gtr:id><gtr:impact>Not yet, but one of our genes of interest is a year 1 priority KO mouse target.</gtr:impact><gtr:outcomeId>betKxh5DXUB-1</gtr:outcomeId><gtr:piContribution>I joined a UK multicentre consortium (Tissue Remodelling and Fibrosis Consortium) and our bid for MRC mouse network funding was successful.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University of Edinburgh Careers Fair</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1D025A7D-2902-4920-82DC-4D1B38DBF6F7</gtr:id><gtr:impact>100-200 undergraduate students attended my stand promoting academic medicine.

Some follow-up discussions with interested students.</gtr:impact><gtr:outcomeId>Dtbr95f6SrA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Hampshire)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>07207D07-506B-458A-998F-FA8D4343548B</gtr:id><gtr:impact>School visit - talk about 'liver disease' to ~150 pupils and Q+A classroom visit.

None specifically.</gtr:impact><gtr:outcomeId>kndXsZG1THw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC BMC MAC</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M007588/1</gtr:fundingRef><gtr:id>F0EC4BA0-3C3C-4175-9B95-CE5C1C8A7AA8</gtr:id><gtr:outcomeId>54f86d03888c42.37125576</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25886</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Wellcome Trust Institutional Strategic Support Fund</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A975E6CD-B268-4928-BC7D-B38B16E1A50C</gtr:id><gtr:outcomeId>56d6cc526626f0.85406497</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>E341583E-7680-4D7A-98AF-B086BC77DE9D</gtr:id><gtr:outcomeId>nuscqmvFVaz0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>386000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Intercept Pharmaceuticals Sponsored Research Agreement</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Intercept Pharmaceuticals</gtr:fundingOrg><gtr:id>06AA3AF0-BFD9-4926-AA84-3FC8618445C2</gtr:id><gtr:outcomeId>58c141610ccaa6.33688733</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244706</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust/Scottish Translational Medicine and Therapeutics Initiative</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT 085664</gtr:fundingRef><gtr:id>B6A1A602-F38B-4312-A749-9611BFD3F7AD</gtr:id><gtr:outcomeId>drDHuEcLTiN0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Liver Multiscan is a new MRI acquisition to quantify liver fibrosis, iron and fat patented by Perspectum diagnostics. We are conducting a 2-centre clinical validation trial in Edinburgh and Birmingham funded by TSB. A pilot trial (RIAL study) has already been undertaken: NCT01543646.</gtr:description><gtr:id>CCFFFD32-27CD-4E80-91FC-7CD8F10CB0AC</gtr:id><gtr:impact>Too early to judge but may replace need for liver biopsy in many situations and accelerate drug development in chronic fibrotic liver disease.</gtr:impact><gtr:outcomeId>rUbXfAxzfTy</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Liver Multiscan</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>MRC have just awarded &amp;pound;3.6M via BMC MAC for study 'Autologous macrophage therapy for liver cirrhosis' (Professor SJ Forbes CI,; Dr JA Fallowfield co-I). Start date was Feb 2015 for 5 years.</gtr:description><gtr:id>C2E6013E-5B26-42F4-BAC8-C065C0A138BC</gtr:id><gtr:impact>Process optimisation. GMP grade production of cell therapy product and in vitro characterisation etc published.</gtr:impact><gtr:outcomeId>F581C66B6F9</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Autologous macrophage infusion</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Non-invasive assessment of liver disease in rodent models using multiparameter MRI - pilot study undertaken. Addresses the 3Rs as it may change the way we model/monitor liver disease in preclinical models - serial measurements as opposed to multiple timepoint culls. Same technology as clinical LiverMultiscan MRI but we miniaturised/developed the platform for our small animal MRI scanner.</gtr:description><gtr:id>BD81994B-E26F-4A73-9FCA-C703A594B1D7</gtr:id><gtr:impact>Presented data (poster) at local 3Rs conference.</gtr:impact><gtr:outcomeId>58c147ce300748.79822388</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Preclinical LiverMultiscan MRI</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>http://perspectum-diagnostics.com/</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D4F1D9F0-3ACE-4774-98F1-8ED4F790AB1D</gtr:id><gtr:title>Liver fibrosis and repair: immune regulation of wound healing in a solid organ.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3c4db5444be357dea85492f795ee6a"><gtr:id>3d3c4db5444be357dea85492f795ee6a</gtr:id><gtr:otherNames>Pellicoro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>545b6414ba6b40.26801246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CE1AB2F-314F-4FEE-A470-AF15521A1498</gtr:id><gtr:title>Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>344A3FC4C04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C39A62C-979B-48BE-995C-DCB9F144D482</gtr:id><gtr:title>Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>Qj9eEMWjBhy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>295C122E-8FE3-4DE7-8616-D28408797046</gtr:id><gtr:title>Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible?</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa98b3b0aefc4e541075c1cb4fe0cfc0"><gtr:id>aa98b3b0aefc4e541075c1cb4fe0cfc0</gtr:id><gtr:otherNames>Fallowfield J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>ZfFUmABKwXK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33EB95FB-5D09-4161-96AF-35B4A65AC18A</gtr:id><gtr:title>Senescence of activated stellate cells: not just early retirement.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f37697b0f9be7a9abefc1217f1cecb1"><gtr:id>6f37697b0f9be7a9abefc1217f1cecb1</gtr:id><gtr:otherNames>Schrader J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>7FB81A3F9EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D0580AF-7E23-4B3C-B00C-CB973D82D160</gtr:id><gtr:title>Therapeutic targets in liver fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>ZWzgDKWeraV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC554D4F-FCB2-44CC-8387-F7BA4F08B4FE</gtr:id><gtr:title>?-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5161c8803a66c22f1413fddae8ebae98"><gtr:id>5161c8803a66c22f1413fddae8ebae98</gtr:id><gtr:otherNames>Morling JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>566ee49da21b16.27104762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E984B893-1690-48FC-B9B0-54B3BB1D9C84</gtr:id><gtr:title>Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5161c8803a66c22f1413fddae8ebae98"><gtr:id>5161c8803a66c22f1413fddae8ebae98</gtr:id><gtr:otherNames>Morling JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_14980_013_10_017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62B2220B-E6F1-4A02-8807-C714758FFAFD</gtr:id><gtr:title>Models and mechanisms of fibrosis resolution.</gtr:title><gtr:parentPublicationTitle>Alcoholism, clinical and experimental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4d3b6f56f87ded49b6c45e9dea5853"><gtr:id>7a4d3b6f56f87ded49b6c45e9dea5853</gtr:id><gtr:otherNames>Snowdon VK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0145-6008</gtr:issn><gtr:outcomeId>aKjeMaVB8w4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0588EC05-A8B6-48F3-A552-505C85FFA011</gtr:id><gtr:title>Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5161c8803a66c22f1413fddae8ebae98"><gtr:id>5161c8803a66c22f1413fddae8ebae98</gtr:id><gtr:otherNames>Morling JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>566ee49d2bdc98.87690439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADCF0E24-5179-404B-9790-C84C4F2B000B</gtr:id><gtr:title>Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5161c8803a66c22f1413fddae8ebae98"><gtr:id>5161c8803a66c22f1413fddae8ebae98</gtr:id><gtr:otherNames>Morling JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>pm_14980_20_24237940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37B1B4BF-6B85-4B8F-9AF7-1FCC1DB4AED7</gtr:id><gtr:title>Resolution of liver fibrosis: basic mechanisms and clinical relevance.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn><gtr:outcomeId>566ee49d55d2c9.24643191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B52E9953-8A7F-4F47-A636-862BFAA4B40B</gtr:id><gtr:title>In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe850fd2185775a32e2d3114aa1f4703"><gtr:id>fe850fd2185775a32e2d3114aa1f4703</gtr:id><gtr:otherNames>McBride A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a785009224bf8.97017065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98D11AEF-79B6-4532-91EE-936F27F32FB5</gtr:id><gtr:title>Macrophage-derived vascular endothelial growth factor and angiogenesis within the hepatic scar-new pathways unmasked in the resolution of fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa98b3b0aefc4e541075c1cb4fe0cfc0"><gtr:id>aa98b3b0aefc4e541075c1cb4fe0cfc0</gtr:id><gtr:otherNames>Fallowfield J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>566ee49dceac41.94237312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE90CA62-5FFB-4AF3-81E9-1F43745715A6</gtr:id><gtr:title>Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14980_20_23100531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDE03609-D7B4-4DC8-A437-BCDF926AEFE9</gtr:id><gtr:title>Reversal of fibrosis: no longer a pipe dream?</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>F3B8774F335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>418291AB-B584-4056-B3E7-52E715E029A1</gtr:id><gtr:title>Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5a7850c7057bf9.23859968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6B13CBC-F3A5-4A0C-B10D-E234B3880472</gtr:id><gtr:title>Future mechanistic strategies for tackling fibrosis--an unmet need in liver disease.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>566ee49d0013c0.13877880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF5ABAA7-4BB9-475F-AC47-8111CC78DA8B</gtr:id><gtr:title>Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3c4db5444be357dea85492f795ee6a"><gtr:id>3d3c4db5444be357dea85492f795ee6a</gtr:id><gtr:otherNames>Pellicoro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_14980_20_22223197</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6205</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>